Cargando…

Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo

BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) is an animal model that captures many of the hallmarks of human multiple sclerosis (MS), including blood–brain barrier (BBB) breakdown, inflammation, demyelination and axonal destruction. The standard clinical score measurement of disease s...

Descripción completa

Detalles Bibliográficos
Autores principales: Eaton, Valerie L, Vasquez, Kristine O, Goings, Gwendolyn E, Hunter, Zoe N, Peterson, Jeffrey D, Miller, Stephen D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225609/
https://www.ncbi.nlm.nih.gov/pubmed/24237884
http://dx.doi.org/10.1186/1742-2094-10-138
_version_ 1782343541037465600
author Eaton, Valerie L
Vasquez, Kristine O
Goings, Gwendolyn E
Hunter, Zoe N
Peterson, Jeffrey D
Miller, Stephen D
author_facet Eaton, Valerie L
Vasquez, Kristine O
Goings, Gwendolyn E
Hunter, Zoe N
Peterson, Jeffrey D
Miller, Stephen D
author_sort Eaton, Valerie L
collection PubMed
description BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) is an animal model that captures many of the hallmarks of human multiple sclerosis (MS), including blood–brain barrier (BBB) breakdown, inflammation, demyelination and axonal destruction. The standard clinical score measurement of disease severity and progression assesses functional changes in animal mobility; however, it does not offer information regarding the underlying pathophysiology of the disease in real time. The purpose of this study was to apply a novel optical imaging technique that offers the advantage of rapid imaging of relevant biomarkers in live animals. METHODS: Advances in non-invasive fluorescence molecular tomographic (FMT) imaging, in combination with a variety of biological imaging agents, offer a unique, sensitive and quantifiable approach to assessing disease biology in living animals. Using vascular (AngioSense 750EX) and protease-activatable cathepsin B (Cat B 680 FAST) near infrared (NIR) fluorescence imaging agents to detect BBB breakdown and inflammation, respectively, we quantified brain and spinal cord changes in mice with relapsing-remitting PLP(139-151)-induced EAE and in response to tolerogenic therapy. RESULTS: FMT imaging and analysis techniques were carefully characterized and non-invasive imaging results corroborated by both ex vivo tissue imaging and comparison to clinical score results and histopathological analysis of CNS tissue. FMT imaging showed clear differences between control and diseased mice, and immune tolerance induction by antigen-coupled PLGA nanoparticles effectively blocked both disease induction and accumulation of imaging agents in the brain and spinal cord. CONCLUSIONS: Cat B 680 FAST and AngioSense 750EX offered the combination best able to detect disease in both the brain and spinal cord, as well as the downregulation of disease by antigen-specific tolerance. Non-invasive optical tomographic imaging thus offers a unique approach to monitoring neuroinflammatory disease and therapeutic intervention in living mice with EAE.
format Online
Article
Text
id pubmed-4225609
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42256092014-11-11 Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo Eaton, Valerie L Vasquez, Kristine O Goings, Gwendolyn E Hunter, Zoe N Peterson, Jeffrey D Miller, Stephen D J Neuroinflammation Research BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) is an animal model that captures many of the hallmarks of human multiple sclerosis (MS), including blood–brain barrier (BBB) breakdown, inflammation, demyelination and axonal destruction. The standard clinical score measurement of disease severity and progression assesses functional changes in animal mobility; however, it does not offer information regarding the underlying pathophysiology of the disease in real time. The purpose of this study was to apply a novel optical imaging technique that offers the advantage of rapid imaging of relevant biomarkers in live animals. METHODS: Advances in non-invasive fluorescence molecular tomographic (FMT) imaging, in combination with a variety of biological imaging agents, offer a unique, sensitive and quantifiable approach to assessing disease biology in living animals. Using vascular (AngioSense 750EX) and protease-activatable cathepsin B (Cat B 680 FAST) near infrared (NIR) fluorescence imaging agents to detect BBB breakdown and inflammation, respectively, we quantified brain and spinal cord changes in mice with relapsing-remitting PLP(139-151)-induced EAE and in response to tolerogenic therapy. RESULTS: FMT imaging and analysis techniques were carefully characterized and non-invasive imaging results corroborated by both ex vivo tissue imaging and comparison to clinical score results and histopathological analysis of CNS tissue. FMT imaging showed clear differences between control and diseased mice, and immune tolerance induction by antigen-coupled PLGA nanoparticles effectively blocked both disease induction and accumulation of imaging agents in the brain and spinal cord. CONCLUSIONS: Cat B 680 FAST and AngioSense 750EX offered the combination best able to detect disease in both the brain and spinal cord, as well as the downregulation of disease by antigen-specific tolerance. Non-invasive optical tomographic imaging thus offers a unique approach to monitoring neuroinflammatory disease and therapeutic intervention in living mice with EAE. BioMed Central 2013-11-15 /pmc/articles/PMC4225609/ /pubmed/24237884 http://dx.doi.org/10.1186/1742-2094-10-138 Text en Copyright © 2013 Eaton et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Eaton, Valerie L
Vasquez, Kristine O
Goings, Gwendolyn E
Hunter, Zoe N
Peterson, Jeffrey D
Miller, Stephen D
Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
title Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
title_full Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
title_fullStr Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
title_full_unstemmed Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
title_short Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
title_sort optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225609/
https://www.ncbi.nlm.nih.gov/pubmed/24237884
http://dx.doi.org/10.1186/1742-2094-10-138
work_keys_str_mv AT eatonvaleriel opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo
AT vasquezkristineo opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo
AT goingsgwendolyne opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo
AT hunterzoen opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo
AT petersonjeffreyd opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo
AT millerstephend opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo